CClinicalTrials.gg
Active, not recruitingNCT05137210IDEaLUpdated Jul 6, 2023

Identifying Efficient Linkage Strategies for Men

An interventional study of Male Counseling and Facility Navigation and Home-Based ART Initiation and Facility Navigation in Hiv, sponsored by University of California, Los Angeles. Active, not recruiting at 1 site in Malawi. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 6 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
569
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

HIV self-testing (HIVST) has been found to be a highly acceptable approach for men to learn of their HIV status and has resulted in increased testing uptake. However, rates of antiretroviral therapy (ART) initiation among those tested with HIVST are difficult to capture. This clinical trial will test varying approaches to ART initiation and retention among men who test positive using HIVST to learn about the most effective strategy to engage men in ART services.

Read the detailed description

HIV self-testing (HIVST) has been found to be a highly acceptable approach for men to learn of their HIV status and has resulted in increased testing uptake. However, rates of antiretroviral therapy (ART) initiation among those tested with HIVST are difficult to capture and some studies have suggested that linkage rates are low , particularly amongst men. The investigators propose a clinical trial to test varying approaches to ART initiation and retention among men who test HIV-positive through HIVST. Three interventions will be tested:

Standard of Care (Arm 1): phone and in-person follow-up, accompanied with male-specific counseling (given every two weeks for up to 90-days or until ART initiation is achieved, whichever comes first); Home-Based ART initiation (Arm 2): nurse-led ART initiation at home or in the community Staged Intervention (Arm 3): a staged intervention that consecutively increases in intensity every month that a participant does not initiate ART (intervals include: Days 1-14: Standard of Care; Days 14-30: Peer support with a psychosocial consellor; Days 30-90: Nurse-led Home-Based ART initiation);

The primary objective is to identify a cost-effective package comprised of male-specific counseling, peer support, community ART distribution and/or home-based ART services for ART initiation and retention among men identified as HIV-positive through HIVST in Malawi. The specific objectives are:

Aim 1. Evaluate the effectiveness of the Stepped ART Intervention (Arm 3) vs male counseling and facility navigation (Arm 1) (primary analysis) and the effectiveness of the Stepped ART Intervention (Arm 3) vs home-based ART initiation with a nurse (Arm 2) (secondary analysis) on ART initiation within 4-months after enrollment in the trial.

Aim 2. Identify individual-, community-, and facility-level factors associated with ART initiation within each intervention arm (male counseling, home-based ART and Stepped intervention) using baseline and semi-structured in-depth interviews.

Aim 3. Determine the cost-effectiveness and scalability of the intervention arms through costing and mathematical modeling.

An individually randomized control trial will be performed with 545 HIV-positive men. Men will be individually randomized 1:1:1 to one of the three intervention arms described above. They will receive their assigned intervention over the course of three months or until the participant initiates ART. The study will be preformed at 10 health facilities supported by Partners in Hope (PIH). Data collection will include baseline and follow-up surveys at 2- and 4-months; medical charter reviews at 2- and 4-months after study enrollment; qualitative interviews with a subset of men and their female partners; and a cost analysis of costs associated with each arm. Male participants will be enrolled in the study for a total of 4 months.

The investigators anticipate learning about the most effective stragty to engage men in ART. The investigators also anticipate learning about the type and degree of followup necessary to support men's engagement in ART services. Finally, the investigators anticipate learning about the cost-effectiveness of intervention, with the goal of improving cost-effectiveness for the Ministry of Health. Results from this study could be used to define best practices and to further scale ART-focused programs for men in Malawi.

02

Conditions studied

  • Hiv

Keywords

  • HIV self-testing (HIVST)
  • HIV
  • Antiretroviral therapy (ART)
  • ART Initiation
  • ART Retention
  • Men
  • HIVST
03

In context

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Men:

Inclusion Criteria:

  • ≥15 years of age
  • Tested HIV positive using Ministry of Health standard algorithm (Determine + Unigold)
  • Not currently engaged in ART services, defined as:

    • Tested HIV-positive ≥14 days and not on ART ≥14 days after testing HIV-positive;
    • ≥14 days late for the first four-week follow up appointment; or
    • Initiated ART but ≥60 days late for last ART appointment;
    • Has not taken ART in the past 7-days, as indicated by a point of care (POC) urine assay
    • Living inside the facility catchment area (defined as any area that HCWs from the study facility routinely visit for tracing purposes)

Exclusion Criteria:

  • \<15 years of age
  • Never tested HIV positive using Ministry of Health standard algorithm (Determine + Unigold)
  • Tested HIV-positive \<14 days ago
  • Currently engaged in ART services, defined as:

    • Initiated ART
    • \<14 days late for the first four-week follow up appointment
    • Initiated ART and \<60 days late for last ART appointment
    • Has taken ART in the past 7-days, as indicated by a point of care (POC) urine assay
    • Living outside the facility catchment area (defined as any area that HCWs from the study facility routinely visit for tracing purposes)

Female partner

Inclusion Criteria:

  • ≥15 years of age
  • Male partner enrolled in the study
  • Male partner agrees that the female can be recruited for an in-depth interview

Exclusion Criteria:

  • \<15 years of age
  • Male partner is not enrolled in the study
  • Male partner does not agree that the female can be recruited for an in-depth interview
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
569 participants (actual)

Study arms

  • Experimental
    Male-specific counseling and facility navigation

    Other: Male Counseling and Facility Navigation

  • Experimental
    Home-Based ART Initiation

    Other: Home-Based ART Initiation and Facility Navigation

  • Experimental
    Stepped Intervention

    Other: Stepped Intervention

Interventions

  • OtherMale Counseling and Facility Navigation

    At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.

  • OtherHome-Based ART Initiation and Facility Navigation

    At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a "warm handover" for their 4-week ART follow-up visit.

  • OtherStepped Intervention

    Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the "Home-Based ART Initiation" Arm.

06

What researchers measure

Primary outcomes

  1. Proportion of men who are retained on ART early

    Proportion of men who initiate ART at 3-months and attended their 4-week ART refill appointment at 4-month after enrollment. Sourced from medical chart reviews.

    Time frame: 4-months.

Secondary outcomes

  1. Proportion of men who initiate ART

    Proportion of men who initiate at 3-months after enrollment. Sourced from medical chart reviews.

    Time frame: 3-months

  2. Any adverse events self-reported by female ART client or male partner

    Self-report of any adverse event from female ART client (IPV, unwanted disclosure, end of relationship) and their male partners (unwanted disclosure) who were identified as HIV-positive. Sourced from follow-up surveys.

    Time frame: 4-months

07

Study locations

1 site
  • Partners in Hope
    Lilongwe, Malawi
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in an article after deidentification (text, tables, figures and appendices).

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05137210
Lead sponsor
University of California, Los Angeles
Collaborators
Partners in Hope, Inc., Boston University, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Charles University, Czech Republic, Bill and Melinda Gates Foundation
Responsible party
Kathryn L. Dovel, PhD (Assistant Professor, University of California, Los Angeles) — Principal investigator
First posted
Nov 30, 2021
Start date
Sep 1, 2021
Primary completion
Mar 15, 2025 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Jul 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion